Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

For the first time, a baby boy has been born to a mother with a womb transplanted from a deceased donor at Queen Charlotte’s and Chelsea hospital in London.

Weighing merely 3.09kg (6lb 13oz), Hugo Powell was born to Grace Bell and Steve Powell from Kent, right before Christmas 2025. "It's simply a miracle. I never, ever thought that this would be possible," Bell said. "I'm the happiest I've ever been in my life. When I was 16, I was told that this would never be possible," she said of her son's birth.

The father added: "When he came over the curtain, it was just sort of overwhelming emotions. I felt like I wanted to cry, but couldn't. From where we started - first meeting - to where we are today, with Hugo, is nothing short of a miracle after everything we've been through. It just felt quite unreal at the time, because this has been a long journey for us both."

The couple also paid tribute to the "kindness and selflessness" of their transplant donor and her family for their "incredible gift", while also thanking medical teams in Oxford and London who supported their journey.

"There are no words to say thank you enough to my donor and her family. Their kindness and selflessness to a complete stranger is the reason I have been able to fulfil my lifelong dream of being a mum.

"I hope they know that my child will always know of their incredible gift, and the miracle that brought him into this world," Bell said.

What Is Mayer-Rokitansky-Kuster-Hauser Disorder?

Bell, an IT programme manager, was born with Mayer-Rokitansky-Kuster-Hauser (MRKH), a disorder that causes the vagina and uterus to be underdeveloped or absent. MRKH syndrome is also called:

• Müllerian agenesis
• Müllerian aplasia
• Congenital absence of the uterus and vagina
• Rokitansky syndrome

While women with MRKH syndrome have normal external genitalia, functioning ovaries, breast and pubic hair development, they are unable to carry a pregnancy and rely on either surrogacy or a womb transplant, as in the case of Bell.

There are two versions of the disorder:

• Type 1: The patient has normally functioning ovaries and fallopian tubes but a blocked or missing upper vagina, cervix and uterus. No other organs are affected.
• Type 2: The patient has a blocked or missing upper vagina, cervix and uterus as well as issues with ovaries, fallopian tubes, spine, kidneys or other organs.

However, these genetic changes have been found in only a small number of affected people and subsequent studies have not identified a clear association between MRKH syndrome and any specific environmental factors. It remains unclears whether they actually cause MRKH syndrome.

Treatment for MRKH depends on the patient's goals and symptoms and some options include:

• Vaginal dilators: Dilators are made of plastic or silicone and vary in length and width. These tubelike devices help expand and stretch the inside of the vagina.
• Vaginoplasty: This is a surgical procedure to create a vagina. There are several ways surgeons perform vaginoplasty, but most involve creating a hole and lining it with tissue from another part of your body.
• Uterus transplant: This is a major surgery that involves placing a donor uterus inside someone without a uterus. Uterine transplants give people with MRKH an opportunity to carry and deliver a child. Uterus transplants are rare.

How Did Bell Conceive Her Child?

"I still can't believe that I'm here today and I've gone through this. It's just amazing."

At the age of 16, the new mother was told she wouldn't be able to carry her own child. However, in 2024 she received a phone call saying a womb had been donated and a transplant was possible, a moment she recalls left her "in complete shock" and "really excited".

Bell's womb transplant operation lasted 10 hours and took place at The Churchill Hospital in Oxford in June 2024 After her transplant surgery, she began fertility treatments several months after the transplant in 2024 and her son was born a year later.

According to The Guardian, Bell's transplanted womb will be removed when the couple have finished having children, to save her from a lifetime of taking immunosuppressant drugs.

15 US states sued President Donald Trump led administration after the Department of Health and Human Services led by Health Secretary Robert F Kennedy Jr. revised vaccine schedule that led to coverage fall from 17 to 11 diseases for children. These 15 states are led Democrats and on Tuesday, they announced suing the Trump administration over unscientific grounds of releasing a new vaccine schedule.

The lawsuit has been filed by a coalition of 14 attorneys general and the governor of Pennsylvania. They have asked the courts to nullify the administration's decision to reduce the number of diseases children are routinely immunized from 17 to 11.

The lawsuit also challenges "the unlawful replacement" of members of the federal Advisory Committee on Immunization Practices, who recommend vaccines for Americans. The lawsuit names the Department of Health and Human Services and Health Secretary Robert F Kennedy Jr as defendants. It also names the Centers for Disease Control and Prevention and its acting director, Dr Jay Bhattacharya.

Read: CDC Vaccine Schedule: Coverage Falls From 17 to 11 Diseases For Children

15 States Sue Trump Administration Over Revised Vaccine Schedule: What Do The States Want?

In a news briefing on Tuesday, Rob Bonta, attorney general of California said, "H.H.S. Secretary R.F.K. Jr. and his C.D.C. are flouting decades of scientific research, ignoring credible medical experts, and threatening to strain state resources and make America’s children sicker.” Bonta continued, "The fact is, vaccines save lives and save our state’s money."

The lawsuit also notes that the administration's revised vaccination schedule was unscientific and relied instead on comparisons to countries that are different than the United States.

Kris Mayes, attorney general of Arizona, as reported by The New York Times said that the latest vaccine schedule "copies" Denmark's recommendation, where the country already has a nationalized health care and the population is fraction of that of the US. "Copying Denmark’s vaccine schedule without copying Denmark’s health care system doesn’t give families more options — it just leaves kids unprotected from serious diseases."

Also Read: Wegovy And Ozempic Will Cost Less In 2027, Novo Nordisk Slashes Weight Loss Drugs Prices By Half

15 States Sue Trump Administration Over Revised Vaccine Schedule: What Is The Revised Vaccine Schedule?

On January 5, 2026, the federal health officials led by RFK Jr. announced that the new Centers for Disease Control and Prevention (CDC), vaccine schedule will include routine shots for 11 diseases for children. This is down from 17 diseases, which were earlier included.

Under the revised schedule, vaccines for a limited number of diseases remain universally recommended for children. These include protection against measles, polio, and whooping cough, which are still considered essential routine immunizations.

Vaccines No Longer Recommended for All Children

The most controversial change is the narrowing of recommendations for several common childhood vaccines. Immunization against the following illnesses is now advised only for high-risk children or after consultation with a health care provider:

• Hepatitis A
• Hepatitis B
• Meningococcal disease
• Rotavirus
• Influenza
• Respiratory syncytial virus, or RSV

Covid-19 vaccination has also shifted to a consultation-based recommendation rather than routine use for all children.

This means shots that were once automatically given at set ages, including at birth, during infancy, and in adolescence, may now depend on individual medical discussions rather than standard guidance.

Wegovy and Ozempic will cost less by January 1 of 2027 as manufacturer Novo Nordisk announced that the prices will be cut in half. The manufacturer said that the popular GLP-1 weight loss drugs will be as much as 50 per cent.

Wegovy and Ozempic Will Cost Less In 2027: How Cheap Can You Get Your Weight Loss Drugs For?

• The list price of Wegovy injections and the new Wegovy pill will be cut in half
• Ozempic injections will be cut by 35 per cent

The manufacturer noted that this cut applies to all doses and the semaglutide tablet Rybelsus will now cost $675 a month. Rybelsus has been approved by the US Food and Drug Administration (FDA) to reduce the risk of heart attacks in those with diabetes.

Read: Doctor Explains Why Weight Loss Drugs Like Ozempic Are Truly A Medical Breakthrough

In a statement to PEOPLE, Jamey Millar, Executive Vice President, US Operations of Novo Nordisk Inc. said, "There are more than 100 million people living with obesity and over 35 million with type 2 diabetes and, for some, list price has been a real barrier to access and affordability."

Wegovy and Ozempic Will Cost Less In 2027: What Are The Current Price?

Wegovy injections and pills currently cost $1,349.02 a month, whereas Ozempic and Rybelus cost $1,027.51. These figures have been emailed to PEOPLE by Novo Nordisk.

Read: GLP-1 Drugs Don’t Just Curb Appetite; They Rewire the Brain, Shows Study

People with commercial insurance pay $25 a month, whereas those using cash pay between $149 to $499. Patients on Medicare will pay $274 per month.

Wegovy and Ozempic Will Cost Less In 2027: How Do GLP-1 Weight Loss Drugs Work?

GLP-1 drugs mimic the action of the natural hormone GLP-1 to regulate blood sugar and promote weight loss. They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake.

Read: Zepbound Outperforms Other Weight Loss Drugs, More Details Inside

In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate pancreas to release insulin and suppress the release of another hormone called glucagon.

These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

In September 2025, WHO added GLP-1 drugs to its list of essential medicines, but only for treating diabetes, not for obesity alone. The new guideline extends that conversation, offering a more formal stance on their use in obesity management. The recommendations were developed by a committee of experts in obesity, pharmacology, and public health, following requests from several WHO member states. They also align with approvals already granted by regulators like the US FDA.